<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Epidemiology and Infectious Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Epidemiology and Infectious Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология и инфекционные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">3034-2007</issn><issn publication-format="electronic">3034-2015</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">701378</article-id><article-id pub-id-type="doi">10.17816/EID701378</article-id><article-id pub-id-type="edn">MKOEYK</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Equal yet different: a comparative characterization of <italic>Ruthenibacterium lactatiformans</italic> and <italic>Faecalibacterium prausnitzii</italic></article-title><trans-title-group xml:lang="ru"><trans-title>Равные, но разные: сравнительная характеристика <italic>Ruthenibacterium lactatiformans</italic> и <italic>Faecalibacterium prausnitzii</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7637-9879</contrib-id><contrib-id contrib-id-type="spin">5956-7634</contrib-id><name-alternatives><name xml:lang="en"><surname>Das</surname><given-names>Milana S.</given-names></name><name xml:lang="ru"><surname>Дас</surname><given-names>Милана Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>milanadas@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4099-2967</contrib-id><contrib-id contrib-id-type="spin">7255-4454</contrib-id><name-alternatives><name xml:lang="en"><surname>Podoprigora</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Подопригора</surname><given-names>Ирина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>podoprigora-iv@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1372-5257</contrib-id><contrib-id contrib-id-type="spin">4340-5962</contrib-id><name-alternatives><name xml:lang="en"><surname>Yashina</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Яшина</surname><given-names>Наталия Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. биол. наук, доцент</p></bio><email>yashina-nv@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4981-0149</contrib-id><contrib-id contrib-id-type="spin">2658-3063</contrib-id><name-alternatives><name xml:lang="en"><surname>Senyagin</surname><given-names>Alexsander N.</given-names></name><name xml:lang="ru"><surname>Сенягин</surname><given-names>Александр Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>senyagin-an@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7046-0799</contrib-id><contrib-id contrib-id-type="spin">1650-0831</contrib-id><name-alternatives><name xml:lang="en"><surname>Tokmalaev</surname><given-names>Anatoly K.</given-names></name><name xml:lang="ru"><surname>Токмалаев</surname><given-names>Анатолий Карпович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>tokmalaev-ak@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9178-5736</contrib-id><contrib-id contrib-id-type="spin">8078-0470</contrib-id><name-alternatives><name xml:lang="en"><surname>Orlova</surname><given-names>Valentina S.</given-names></name><name xml:lang="ru"><surname>Орлова</surname><given-names>Валентина Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology), Professor</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор</p></bio><email>orlova-vs@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8879-6516</contrib-id><contrib-id contrib-id-type="spin">3056-5899</contrib-id><name-alternatives><name xml:lang="en"><surname>Efimov</surname><given-names>Boris A.</given-names></name><name xml:lang="ru"><surname>Ефимов</surname><given-names>Борис Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>efimov_ba@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia (RUDN University)</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов им. Патриса Лумумбы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-03-06" publication-format="electronic"><day>06</day><month>03</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-03-31" publication-format="electronic"><day>31</day><month>03</month><year>2026</year></pub-date><volume>31</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>51</fpage><lpage>63</lpage><history><date date-type="received" iso-8601-date="2026-01-21"><day>21</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-01-27"><day>27</day><month>01</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-вектор</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-03-31"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjeid.com/1560-9529/article/view/701378">https://rjeid.com/1560-9529/article/view/701378</self-uri><abstract xml:lang="en"><p>The gut microbiota plays a key role in maintaining human homeostasis. Of particular interest are 2 bacterial species of the family <italic>Oscillospiraceae</italic>: the well-studied <italic>Faecalibacterium prausnitzii</italic>, with proven anti-inflammatory properties, and the recently described <italic>Ruthenibacterium lactatiformans</italic>, whose functional potential remains insufficiently investigated. Despite their phylogenetic proximity, these species differ substantially in metabolic properties, associations with pathological conditions, and probiotic potential. The work aimed to conduct a comparative analysis of the characteristics of <italic>F. prausnitzii </italic>and <italic>R. lactatiformans</italic> and their interactions with the host, as well as to summarize data on possible mechanisms underlying their influence on the development of a wide range of diseases, including inflammatory bowel diseases, cardiovascular, metabolic, neurologic, and oncologic diseases.</p> <p>Studies demonstrate that reduced abundance of <italic>F. prausnitzii</italic> serves as a reliable biomarker of dysbiosis and is associated with chronic inflammatory, autoimmune, and metabolic diseases. The protective role of this bacterium is primarily related to butyrate production and immunomodulation. In contrast to <italic>F. prausnitzii</italic>, associations of <italic>R. lactatiformans</italic> with pathological conditions are inconsistent. Increased abundance of this species correlates with both pathological states (stroke, active multiple sclerosis) and periods of clinical remission in certain diseases. At the same time, in experimental models, <italic>R. lactatiformans</italic> demonstrates protective, particularly metabolic, properties.</p> <p>The decrease in <italic>F. prausnitzii</italic> abundance under pathological conditions is likely explained by its sensitivity to environmental changes such as tissue acidosis and oxidative stress. In contrast, <italic>R. lactatiformans</italic>, owing to greater metabolic plasticity (ability to produce lactate and acetate) and relative aerotolerance, is capable of adapting to these unfavorable conditions.</p> <p>In conclusion, we support the hypothesis that the observed changes may reflect a dynamic dysbiotic shift and potential synergism rather than competition: <italic>R. lactatiformans</italic>, acting as an adaptive substrate supplier, may contribute to restoration of conditions favorable for subsequent colonization by butyrate-producing bacteria such as <italic>F. prausnitzii</italic>. This opens new perspectives for the development of probiotic strategies based on synergistic bacterial consortia.</p></abstract><trans-abstract xml:lang="ru"><p>Микробиота кишечника играет ключевую роль в поддержании гомеостаза организма человека. Особый интерес представляют два вида бактерий из семейства <italic>Oscillospiraceae</italic>: хорошо изученный <italic>Faecalibacterium prausnitzii</italic>, обладающий доказанными противовоспалительными свойствами, и недавно описанный <italic>Ruthenibacterium lactatiformans</italic>, функциональный потенциал которого остаётся малоисследованным. Несмотря на филогенетическую близость, эти виды бактерий существенно различаются по метаболическим свойствам, ассоциации с патологиями и пробиотическому потенциалу. Цель настоящего обзора — провести сравнительный анализ характеристик <italic>F. prausnitzii</italic> и <italic>R. lactatiformans</italic>, и их взаимодействия с организмом хозяина, а также обобщить данные о возможных механизмах их влияния на развитие широкого спектра заболеваний, включая воспалительные болезни кишечника, сердечно-сосудистые, метаболические и неврологические расстройства, а также онкопатологию.</p> <p>Исследования показывают, что снижение численности <italic>F. prausnitzii</italic> служит надёжным биомаркёром дисбиоза и ассоциировано с хроническими воспалительными, аутоиммунными и метаболическими заболеваниями. Протективная роль этой бактерии связана в первую очередь с продукцией бутирата и иммуномодуляцией. В отличие от <italic>F. prausnitzii</italic>, ассоциации <italic>R. lactatiformans</italic> с патологиями носят неоднозначный характер. Повышенная представленность этого вида коррелирует как с патологическими состояниями (инсульт, активная фаза рассеянного склероза), так и с периодами клинической ремиссии при некоторых заболеваниях. При этом в экспериментальных моделях <italic>R. lactatiformans</italic> демонстрирует протективные, в частности метаболические, свойства.</p> <p>Вероятно, снижение численности <italic>F. prausnitzii</italic> при патологиях объясняется его чувствительностью к изменениям среды, таким как тканевой ацидоз и окислительный стресс. В то же время <italic>R. lactatiformans</italic>, обладая большей метаболической пластичностью (способностью к продукции лактата и ацетата) и относительной аэротолерантностью, способен адаптироваться к этим неблагоприятным условиям.</p> <p>В заключении мы подтверждаем гипотезу о том, что наблюдаемые изменения могут отражать не конкуренцию, а динамический дисбиотический сдвиг и потенциальный синергизм: <italic>R. lactatiformans</italic>, выступая в роли адаптивного поставщика субстратов, может способствовать восстановлению условий, благоприятных для последующей колонизации бутират-продуцирующими бактериями, такими как <italic>F. prausnitzii</italic>. Это открывает новые перспективы для разработки пробиотических стратегий, основанных на применении синергических бактериальных консорциумов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Ruthenibacterium lactatiformans</kwd><kwd>Faecalibacterium prausnitzii</kwd><kwd>probiotics</kwd><kwd>inflammatory bowel diseases</kwd><kwd>gastrointestinal microbiome</kwd><kwd>review</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Ruthenibacterium lactatiformans</kwd><kwd>Faecalibacterium prausnitzii</kwd><kwd>пробиотики нового поколения</kwd><kwd>воспалительные заболевания кишечника (ВЗК)</kwd><kwd>микробиота кишечника</kwd><kwd>обзор</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Chang C, Yuan X, Zhang X, et al. Gastrointestinal microbiome and multiple health outcomes: umbrella review. Nutrients. 2022;14(18):3726. doi: 10.3390/nu14183726 EDN: JSGPTN</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther. 2010;8(4):435–454. doi: 10.1586/eri.10.14</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sen T, Thummer RP. The impact of human microbiotas in hematopoietic stem cell and organ transplantation. Front Immunol. 2022;13:932228. doi: 10.3389/fimmu.2022.932228 EDN: GRMLKR</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Yoo S, Jung SC, Kwak K, Kim JS. The role of prebiotics in modulating gut microbiota: implications for human health. Int J Mol Sci. 2024;25(9):4834. doi: 10.3390/ijms25094834 EDN: GXBNEQ</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zhu B, Edwards DJ, Spaine KM, et al. The association of maternal factors with the neonatal microbiota and health. Nat Commun. 2024;15(1):5260. doi: 10.1038/s41467-024-49160-w EDN: GJLCTW</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>De Filippis F, Paparo L, Nocerino R, et al. Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance. Nat Commun. 2021;12(1):5958. doi: 10.1038/s41467-021-26266-z EDN: JYGBCJ</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Marcos-Fernández R, Riestra S, Alonso-Arias R, et al. Immunomagnetic capture of Faecalibacterium prausnitzii selectively modifies the fecal microbiota and its immunomodulatory profile. Microbiol Spectr. 2023;11(1):e0181722. doi: 10.1128/spectrum.01817-22 EDN: XCIMEE</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zhao L, Grimes SM, Greer SU, et al. Characterization of the consensus mucosal microbiome of colorectal cancer. NAR Cancer. 2021;3(4):zcab049. doi: 10.1093/narcan/zcab049 EDN: EYSHZV</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841–852. doi: 10.1038/ismej.2016.176 EDN: YWLKON</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736. doi: 10.1073/pnas.0804812105</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Fitzgerald CB, Shkoporov AN, Sutton TDS, et al. Comparative analysis of Faecalibacterium prausnitzii genomes shows a high level of genome plasticity and warrants separation into new species-level taxa. BMC Genomics. 2018;19(1):931. doi: 10.1186/s12864-018-5313-6 EDN: MHBOSS</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Shkoporov AN, Chaplin AV, Shcherbakova VA, et al. Ruthenibacterium lactatiformans gen. nov., sp. nov., an anaerobic, lactate-producing member of the family Ruminococcaceae isolated from human faeces. Int J Syst Evol Microbiol. 2016;66(8):3041–3049. doi: 10.1099/ijsem.0.001143 EDN: XFKZPB</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Rampelli S, Turroni S, Mallol C, et al. Components of a Neanderthal gut microbiome recovered from fecal sediments from El Salt. Commun Biol. 2021;4(1):169. doi: 10.1038/s42003-021-01689-y EDN: RIRPRW</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Prausnitz C. Der Bacillus mucosus anaerobius. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt I Orig. 1922;89:126–132.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hauduroy P, Ehringer G, Guillot G, et al. Dictionnaire des bactéries pathogènes: pour l’homme, les animaux et les plantes. Paris: Masson; 1937.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Cato EP, Salmon CW, Moore WEC. Fusobacterium prausnitzii (Hauduroy et al.) Moore and Holdeman: emended description and designation of neotype strain. Int J Syst Bacteriol. 1974;24(2):225–229.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Collins MD, Lawson PA, Willems A, et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Evol Microbiol. 1994;44(4):812–826.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Duncan SH, Hold GL, Harmsen HJM, et al. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol. 2002;52(Pt 6):2141–2146. doi: 10.1099/00207713-52-6-2141</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. doi: 10.1038/nature09944</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996–1047. doi: 10.1111/1574-6976.12075</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kumar S, Stecher G, Suleski M, et al. MEGA12: molecular evolutionary genetic analysis version 12 for adaptive and green computing. Mol Biol Evol. 2024;41(12):msae263. doi: 10.1093/molbev/msae263 EDN: XJLZTL</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Sumiyoshi S, Hamaguchi S, Kimura K, et al. Ruthenibacterium lactatiformans isolated from a human blood culture: a first report. BMC Infect Dis. 2024;24(1):699. doi: 10.1186/s12879-024-09606-4 EDN: YMBXJT</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hashimoto Y, Hisatsune J, Suzuki M, et al. Elucidation of host diversity of the VanD-carrying genomic islands in enterococci and anaerobes. JAC Antimicrob Resist. 2022;4(1):dlab189. doi: 10.1093/jacamr/dlab189 EDN: IVHFHN</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Blanco G, Sánchez B, Fdez-Riverola F, et al. In silico approach for unveiling the glycoside hydrolase activities in Faecalibacterium prausnitzii through a systematic and integrative large-scale analysis. Front Microbiol. 2019;10:517. doi: 10.3389/fmicb.2019.00517 EDN: WZMXEC</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Geng P, Zhao N, Zhou Y, et al. Faecalibacterium prausnitzii regulates carbohydrate metabolic functions of the gut microbiome in C57BL/6 mice. Gut Microbes. 2025;17(1):2455503. doi: 10.1080/19490976.2025.2455503 EDN: OTULEU</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Dogra SK, Dardinier A, Mainardi F, et al. Application of computational data modeling to a large-scale population cohort assists the discovery of inositol as a strain-specific substrate for Faecalibacterium prausnitzii. Nutrients. 2023;15(6):1311. doi: 10.3390/nu15061311 EDN: EILRXH</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Huang YJ, Lewis CA, Wright C, et al. Faecalibacterium prausnitzii A2-165 metabolizes host- and media-derived chemicals and induces transcriptional changes in colonic epithelium in GuMI human gut microphysiological system. Microbiome Res Rep. 2024;3(3):30. doi: 10.20517/mrr.2024.14 EDN: HPLDND</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Guo Y, Crnkovic CM, Won KJ, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos. 2019;47(3):194–202. doi: 10.1124/dmd.118.084772</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Auger S, Kropp C, Borras-Nogues E, et al. Intraspecific diversity of microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii. Int J Mol Sci. 2022;23(3):1705. doi: 10.3390/ijms23031705 EDN: RRLTQZ</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Miquel S, Leclerc M, Martin R, et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio. 2015;6(2):e00300-15. doi: 10.1128/mBio.00300-15 EDN: UOUOOR</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hammond TC, Powell E, Green SJ, et al. Functional recovery outcomes following acute stroke is associated with abundance of gut microbiota related to inflammation, butyrate and secondary bile acid. Front Rehabil Sci. 2022;3:1017180. doi: 10.3389/fresc.2022.1017180 EDN: IYPXUA</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Li W, Li H, Wang S, et al. Regional pattern and signatures of gut microbiota in rural residents with coronary heart disease: A metagenomic analysis. Front Cell Infect Microbiol. 2022;12:1007161. doi: 10.3389/fcimb.2022.1007161 EDN: QPTVDE</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Xu H, Zhao H, Fan D, et al. Interactions between gut microbiota and immunomodulatory cells in rheumatoid arthritis. Mediators Inflamm. 2020;2020:1430605. doi: 10.1155/2020/1430605 EDN: VNNFJT</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Lee JY, Mannaa M, Kim Y, et al. Comparative analysis of fecal microbiota composition between rheumatoid arthritis and osteoarthritis patients. Genes (Basel). 2019;10(10):748. doi: 10.3390/genes10100748 EDN: ZYRXDU</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Clos-Garcia M, Ahluwalia TS, Winther SA, et al. Multiomics signatures of type 1 diabetes with and without albuminuria. Front Endocrinol (Lausanne). 2022;13:1015557. doi: 10.3389/fendo.2022.1015557 EDN: TKDFCB</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Trivieri N, Pracella R, Cariglia MG, et al. BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. J Exp Clin Cancer Res. 2020;39(1):285. doi: 10.1186/s13046-020-01801-w EDN: WOEOXG</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Sabater C, Calvete-Torre I, Ruiz L, Margolles A. Arabinoxylan and pectin metabolism in Crohn’s disease microbiota: An in silico study. Int J Mol Sci. 2022;23(13):7093. doi: 10.3390/ijms23137093 EDN: QKOKBI</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Jangi S, Zhao N, Hsia K, et al. Specific bacterial co-abundance groups are associated with inflammatory status in patients with ulcerative colitis. J Crohns Colitis. 2025;19(1):jjae125. doi: 10.1093/ecco-jcc/jjae125 EDN: KNQPRH</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Dias BDC, Lamarca AP, Machado DT, et al. Metabolic pathways associated with Firmicutes prevalence in the gut of multiple livestock animals and humans. Anim Microbiome. 2025;7(1):20. doi: 10.1186/s42523-025-00379-y EDN: DUFDDA</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Eckenberger J, Butler JC, Bernstein CN, et al. Interactions between medications and the gut microbiome in inflammatory bowel disease. Microorganisms. 2022;10(10):1963. doi: 10.3390/microorganisms10101963 EDN: KOYAHZ</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Testerman T, Li Z, Galuppo B, et al. Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth. Hepatol Commun. 2022;6(8):1962–1974. doi: 10.1002/hep4.1944 EDN: CRTNEY</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Wu F, Guo Y, Wang Y, et al. Effects of long-term fasting on gut microbiota, serum metabolome, and their association in male adults. Nutrients. 2024;17(1):35. doi: 10.3390/nu17010035 EDN: BIONNE</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Kovtun AS, Averina OV, Angelova IY, et al. Alterations of the composition and neurometabolic profile of human gut microbiota in major depressive disorder. Biomedicines. 2022;10(9):2162. doi: 10.3390/biomedicines10092162 EDN: WVZGWF</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Cox LM, Maghzi AH, Liu S, et al. Gut microbiome in progressive multiple sclerosis. Ann Neurol. 2021;89(6):1195–1211. doi: 10.1002/ana.26084 EDN: AFFKGG</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Zhou X, Baumann R, Gao X, et al. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467–3486.e16. doi: 10.1016/j.cell.2022.08.021 EDN: JFOATQ</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Becker A, Schmartz GP, Gröger L, et al. Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson’s disease - The RESISTA-PD trial. Genomics Proteomics Bioinf. 2022;20(2):274–287. doi: 10.1016/j.gpb.2021.08.009 EDN: ULAIYN</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Wallen ZD, Demirkan A, Twa G, et al. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun. 2022;13(1):6958. doi: 10.1038/s41467-022-34667-x</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Yay E, Yilmaz M, Toygar H, et al. Oral and gut microbial profiling in periodontitis and Parkinson’s disease. J Oral Microbiol. 2024;16(1):2331264. doi: 10.1080/20002297.2024.2331264 EDN: QSAGBF</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Liang S, Mao Y, Liao M, et al. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps. Int J Biol Sci. 2020;16(1):135–146. doi: 10.7150/ijbs.37399 EDN: JVVYIS</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7(29):46158–46172. doi: 10.18632/oncotarget.10064 EDN: WSHXMH</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Jia W, Whitehead RN, Griffiths L, et al. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS Microbiol Lett. 2010;310(2):138–144. doi: 10.1111/j.1574-6968.2010.02057.x EDN: NZHSDD</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Mclellan P, Auger S, Goudiaby MT, et al. Faecalibacterium diversity in the gut microbiome of Crohn’s disease patients. United European Gastroenterol J. 2025;13(8):1480–1490. doi: 10.1002/ueg2.70023 EDN: BIMWZB</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Lopez-Siles M, Khan TM, Duncan SH, et al. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl Environ Microbiol. 2012;78(2):420–428. doi: 10.1128/AEM.06858-11</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Chen SJ, Zhang DY, Wu X, et al. Washed microbiota transplantation for Crohn’s disease: A metagenomic, metatranscriptomic, and metabolomic-based study. World J Gastroenterol. 2024;30(11):1572–1587. doi: 10.3748/wjg.v30.i11.1572 EDN: ZQAJFF</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Basha OM, Hafez RA, Salem SM, et al. Impact of gut microbiome alteration in ulcerative colitis patients on disease severity and outcome. Clin Exp Med. 2023;23(5):1763–1772. doi: 10.1007/s10238-022-00917-x EDN: ZGEJBY</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Xu J, Liang R, Zhang W, et al. Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes. 2020;12(3):224–236. doi: 10.1111/1753-0407.12986</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Chasov V, Gilyazova E, Ganeeva I, et al. Gut microbiota modulation: a novel strategy for rheumatoid arthritis therapy. Biomolecules. 2024;14(12):1653. doi: 10.3390/biom14121653 EDN: XAUQBS</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Vural M, Gilbert B, Üstün I, et al. Mini-review: human microbiome and rheumatic diseases. Front Cell Infect Microbiol. 2020;10:491160. doi: 10.3389/fcimb.2020.491160 EDN: NDUHNO</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Xu X, Zhou J, Xie H, et al. Immunomodulatory mechanisms of the gut microbiota and metabolites on regulatory T cells in rheumatoid arthritis. Front Immunol. 2025;16:1610254. doi: 10.3389/fimmu.2025.1610254 EDN: OJZIUJ</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Cui X, Ye L, Li J, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep. 2018;8(1):635. doi: 10.1038/s41598-017-18756-2 EDN: YFTRZB</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Simadibrata DM, Auliani S, Widyastuti PA, et al. The gut microbiota profile in heart failure patients: A systematic review. J Gastrointestin Liver Dis. 2023;32(3):393–401. doi: 10.15403/jgld-4779 EDN: RFIIMA</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Zheng T, Meng C, Lv Z, et al. The critical role of Faecalibacterium prausnitzii in cardiovascular diseases. Rev Cardiovasc Med. 2025;26(3):26740. doi: 10.31083/RCM26740 EDN: WIRVXH</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Luo Y, Chang G, Yu G, et al. Unveiling the negative association of Faecalibacterium prausnitzii with ischemic stroke severity, impaired prognosis and pro-inflammatory markers. Heliyon. 2024;10(5):e26651. doi: 10.1016/j.heliyon.2024.e26651 EDN: ZVHCUF</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Moran-Ramos S, Macias-Kauffer L, López-Contreras BE, et al. A higher bacterial inward BCAA transport driven by Faecalibacterium prausnitzii is associated with lower serum levels of BCAA in early adolescents. Mol Med. 2021;27(1):108. doi: 10.1186/s10020-021-00371-7 EDN: MRVHGT</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Hensen T, Thiele I. Metabolic modeling links gut microbiota to metabolic markers of Parkinson’s disease. Gut Microbes. 2025;17(1):2554195. doi: 10.1080/19490976.2025.2554195 EDN: SGDEEA</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Rasoulian P, Akhgarjand C, Houjaghani H, et al. Gut dysbiosis in multiple sclerosis patients: a comparative analysis in fecal samples. Sci Rep. 2025;15(1):36009. doi: 10.1038/s41598-025-19998-1 EDN: QREUDN</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Knuesel T, Mohajeri MH. The role of the gut microbiota in the development and progression of major depressive and bipolar disorder. Nutrients. 2021;14(1):37. doi: 10.3390/nu14010037 EDN: CKNSZM</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Ma J, Sun L, Liu Y, et al. Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer. BMC Microbiol. 2020;20(1):82. doi: 10.1186/s12866-020-01739-1 EDN: CMZSFO</mixed-citation></ref></ref-list></back></article>
